Samsung Bioepis, Teva Enter License, Development, Commercialization Agreement For EPYSQLI
Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...
Le Lézard19h
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Vistagen , a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of ...
Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...
Le Lézard19h
The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations, Upcoming Webinar Hosted by Xtalks
For more information, or to register for this event, visit The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations.
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...
The Bakersfield Californian20h
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI®
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...